1. Home
  2. CGON vs ATEN Comparison

CGON vs ATEN Comparison

Compare CGON & ATEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • ATEN
  • Stock Information
  • Founded
  • CGON 2010
  • ATEN 2004
  • Country
  • CGON United States
  • ATEN United States
  • Employees
  • CGON N/A
  • ATEN N/A
  • Industry
  • CGON
  • ATEN EDP Services
  • Sector
  • CGON
  • ATEN Technology
  • Exchange
  • CGON NYSE
  • ATEN Nasdaq
  • Market Cap
  • CGON 1.3B
  • ATEN 1.1B
  • IPO Year
  • CGON 2024
  • ATEN 2014
  • Fundamental
  • Price
  • CGON $24.13
  • ATEN $16.90
  • Analyst Decision
  • CGON Strong Buy
  • ATEN Buy
  • Analyst Count
  • CGON 11
  • ATEN 2
  • Target Price
  • CGON $62.90
  • ATEN $21.00
  • AVG Volume (30 Days)
  • CGON 2.0M
  • ATEN 975.5K
  • Earning Date
  • CGON 05-16-2025
  • ATEN 05-01-2025
  • Dividend Yield
  • CGON N/A
  • ATEN 1.42%
  • EPS Growth
  • CGON N/A
  • ATEN 9.85
  • EPS
  • CGON N/A
  • ATEN 0.67
  • Revenue
  • CGON $1,139,000.00
  • ATEN $267,158,000.00
  • Revenue This Year
  • CGON N/A
  • ATEN $9.23
  • Revenue Next Year
  • CGON $16,237.24
  • ATEN $7.49
  • P/E Ratio
  • CGON N/A
  • ATEN $25.29
  • Revenue Growth
  • CGON 461.08
  • ATEN 4.90
  • 52 Week Low
  • CGON $14.80
  • ATEN $12.27
  • 52 Week High
  • CGON $40.47
  • ATEN $21.90
  • Technical
  • Relative Strength Index (RSI)
  • CGON 51.00
  • ATEN 54.66
  • Support Level
  • CGON $21.00
  • ATEN $15.92
  • Resistance Level
  • CGON $30.23
  • ATEN $17.51
  • Average True Range (ATR)
  • CGON 2.31
  • ATEN 0.53
  • MACD
  • CGON 0.16
  • ATEN 0.19
  • Stochastic Oscillator
  • CGON 34.09
  • ATEN 74.52

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

Share on Social Networks: